Di Stefano, Miriana; Masoni, Samuele; Bononi, Giulia; Poli, Giulio; Galati, Salvatore; Gado, Francesca; Manzi, Simone; Vagaggini, Chiara; Brai, Annalaura; Caligiuri, Isabella; Asif, Kanwal; Rizzolio, Flavio; Macchia, Marco; Chicca, Andrea; Sodi, Andrea; Di Bussolo, Valeria; Minutolo, Filippo; Meier, Philip; Gertsch, Jürg; Granchi, Carlotta; ... (2024). Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors. European journal of medicinal chemistry, 263(115916), p. 115916. Elsevier 10.1016/j.ejmech.2023.115916
|
Text
1-s2.0-S0223523423008838-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview |
The degradation of the endocannabinoid 2-arachidonoylglycerol is mediated by the enzyme monoacylglycerol lipase (MAGL), thus generating arachidonic acid, the precursor of prostaglandins and other pro-inflammatory mediators. MAGL also contributes to the hydrolysis of monoacylglycerols into glycerol and fatty acids in peripheral body districts, which may act as pro-tumorigenic signals. For this reason, MAGL inhibitors have been considered as interesting therapeutic agents for their anti-nociceptive, anti-inflammatory, antioxidant and anti-cancer properties. So far, only a limited series of reversible MAGL inhibitors, which are devoid of side effects shown by irreversible inhibitors in animal models, have been reported. Here we optimized a class of benzylpiperidine and benzylpiperazine-based compounds for a reversible MAGL inhibition. The best MAGL inhibitors of this class, compounds 28 and 29, showed a very good inhibition potency, both on the isolated enzyme and in U937 cells, as confirmed by molecular modeling studies that predicted their binding mode into the MAGL active site. Both compounds are characterized by a high selectivity for MAGL versus other serine hydrolases including enzymes of the endocannabinoid system, as confirmed by ABPP experiments in mouse brain membranes. Moreover, very good properties concerning ADME parameters and low in vivo toxicity have been observed for both compounds.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine |
UniBE Contributor: |
Chicca, Andrea, Meier, Philip, Gertsch, Jürg |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1768-3254 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
21 Nov 2023 15:29 |
Last Modified: |
04 Dec 2023 00:16 |
Publisher DOI: |
10.1016/j.ejmech.2023.115916 |
PubMed ID: |
37976705 |
Uncontrolled Keywords: |
ADME Benzylpiperazine Benzylpiperidine Inhibitors MAGL Monoacylglycerol lipase |
BORIS DOI: |
10.48350/189143 |
URI: |
https://boris.unibe.ch/id/eprint/189143 |